Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

By afschroeder • September 6, 2026

Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West RM, Pillai P, Marinello P, Herrera AF. Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study. Blood Neoplasia. 2026 May 26;3(4):100252. doi: 10.1016/j.bneo.2026.100252. PMID: 42699247; PMCID: PMC13542932.

Tags: Hematology/Oncology, Publications

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark[...]

Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)

Lowenstein LM, Bernal MP, Bergren EP, Busaidy TK, Brauer ER, Ganz PA, Smith GL, Shih YT. Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and[...]

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer

Arbour KC, Punekar S, Luo J, Johnson M, Spira A, Herzberg B, Starodub A, Sommerhalder D, Hecht JR, Garrido-Laguna I, Barve M, Ou SI, Kar[...]